Division of Newron Pharmaceuticals SPA
Latest From NeuroNova AB
Further to a pledge to expedite global filings for the Parkinson's disease (PD) compound safinamide, Newron Pharmaceuticals and its partner Zambon say regulatory submissions are expected in the US and EU in the fourth quarter, for the use of the drug both an add-on therapy to dopamine agonist therapy in patients with early PD and as an add-on to levodopa therapy in patients with advanced PD.
As companies flurried to clinch deals by the end of the year, a number of significant agreements were signed or completed last December.
Newron Pharmaceuticals' management can breathe a sigh of relief: its shareholders have approved its plans to acquire NeuroNova. The Italian firm has announced that it received unanimous approval for revised proposals to acquire the Swedish biotech company at its shareholder meeting (where just over 40% of the shares were represented).
No one would have blamed Rolf Stahel, a Swiss national chairman of Newron, from recalling the English phrase "With friends like this who needs enemies" as Zambon, the company's major pharma partner, voted against plans by the Italian CNS company to acquire Swedish biotech company NeuroNova. Newron's management had hoped shareholders would support its ambition to acquire the Swedish company's pipeline and cash at an emergency general meeting,
- Large Molecule
- Therapeutic Areas
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Newron Pharmaceuticals SPA
- Senior Management
Ulf Ljungberg, PhD, Pres. & CEO
Henrik Resmark, CFO
Anders Haegerstrand, MD, PhD, CSO
- Contact Info
Phone: (46) (0)8 786 0900
Fiskartorpsvägen 15 A-D
Stockholm, SE-114 33
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.